EUR/USD likely to find a peak near 1.25: UBS
Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (NYSE:AIM), recently acquired 83,334 shares of the company’s common stock, according to a regulatory filing with the Securities and Exchange Commission. This insider purchase comes as the stock has declined nearly 70% over the past year, with InvestingPro data showing analyst price targets ranging from $1.00 to $4.50. The shares were purchased at a price of $0.12 per share, amounting to a total transaction value of $10,000. Following this acquisition, Equels now holds a total of 1,764,029 shares directly. AIM ImmunoTech, based in Ocala, Florida, is engaged in the development of biological products. InvestingPro analysis reveals the company maintains a moderate debt level with a weak overall financial health score of 1.37, while operating with an impressive gross profit margin of 81%. Discover more comprehensive insights and 10+ additional ProTips with an InvestingPro subscription.
In other recent news, AIM ImmunoTech Inc. has received approval from the NYSE American for its compliance plan, allowing the company until June 11, 2026, to meet the exchange’s stockholders’ equity requirements. This approval is crucial as it ensures AIM’s continued listing on the exchange. In another development, AIM announced plans to develop its drug Ampligen as a vaccine adjuvant for avian influenza, with Amarex Clinical Research assisting in the process. The company is seeking collaboration from government and industry to support this initiative financially.
Additionally, AIM’s executives have decided to forgo their 2024 cash bonuses to allocate more resources towards research and development, focusing on Ampligen. This decision underscores AIM’s commitment to advancing its drug pipeline. Furthermore, AIM recently concluded its 2024 Annual Meeting of Stockholders, where new directors were elected amid a proxy battle. Shareholders also ratified the selection of BDO USA, P.C. as the independent accounting firm, although a non-binding advisory vote on executive compensation did not pass.
These developments highlight AIM ImmunoTech’s strategic efforts to enhance its research capabilities and maintain corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.